Equities research analysts expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to announce sales of $5.06 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Adamis Pharmaceuticals’ earnings. The highest sales estimate is $6.42 million and the lowest is $4.25 million. Adamis Pharmaceuticals posted sales of $3.39 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 49.3%. The business is expected to report its next quarterly earnings report on Monday, August 13th.
On average, analysts expect that Adamis Pharmaceuticals will report full-year sales of $18.48 million for the current fiscal year, with estimates ranging from $15.85 million to $21.90 million. For the next fiscal year, analysts anticipate that the company will post sales of $32.28 million per share, with estimates ranging from $22.32 million to $47.60 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.10). Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%. The company had revenue of $3.92 million during the quarter, compared to analysts’ expectations of $4.14 million.
NASDAQ:ADMP remained flat at $$3.25 during midday trading on Tuesday. 537,007 shares of the company were exchanged, compared to its average volume of 656,420. Adamis Pharmaceuticals has a 52 week low of $2.35 and a 52 week high of $5.85. The company has a quick ratio of 1.57, a current ratio of 1.88 and a debt-to-equity ratio of 0.07. The company has a market cap of $108.52 million, a price-to-earnings ratio of -3.61 and a beta of 0.45.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADMP. Wells Fargo & Company MN raised its position in shares of Adamis Pharmaceuticals by 1,050.3% during the fourth quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after buying an additional 25,732 shares during the last quarter. Northern Trust Corp boosted its stake in Adamis Pharmaceuticals by 50.7% during the first quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock worth $489,000 after buying an additional 46,924 shares during the period. Dimensional Fund Advisors LP purchased a new position in Adamis Pharmaceuticals during the first quarter worth $244,000. Finally, BlackRock Inc. boosted its stake in Adamis Pharmaceuticals by 7.7% during the second quarter. BlackRock Inc. now owns 293,328 shares of the specialty pharmaceutical company’s stock worth $939,000 after buying an additional 20,871 shares during the period. Institutional investors own 10.72% of the company’s stock.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
See Also: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.